NCT03386201 (FLoCaMB) is a NA clinical trial of Intravenous Methylene blue in Bile Duct Injury, sponsored by University of Oxford.

Who is sponsoring NCT03386201?

NCT03386201 is sponsored by University of Oxford.

What drugs are being tested in NCT03386201?

Interventions in NCT03386201: Intravenous Methylene blue.

What condition does NCT03386201 study?

NCT03386201 studies Bile Duct Injury.

Is NCT03386201 still recruiting?

NCT03386201 is currently status unknown. Last updated 29 December 2017.

Last reviewed 2017-12-29 · How we verify

NCT03386201: FLoCaMB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FLuorescence Cholangiography Using Methylene Blue

Status unknown NA Last updated 29 December 2017

What this trial tests

NA trial testing Intravenous Methylene blue in Bile Duct Injury in 40 participants. Status unknown.

Timeline

1 January 2018

Primary endpoint
1 June 2018

1 June 2018

Quick facts

Lead sponsor	University of Oxford
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	40
Start date	1 January 2018
Primary completion	1 June 2018
Estimated completion	1 June 2018
Sites	1 location across United Kingdom

Drugs / interventions tested

Intravenous Methylene blue — full drug profile →

Conditions studied

Bile Duct Injury — all drugs for Bile Duct Injury →

Sponsor

University of Oxford

Who can join

18 and older, any sex, with Bile Duct Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Open label prospective, non-randomised proof of principle study assessing the use of methylene blue fluorescence cholangiography.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Bile Duct Injury

Currently open trials in the same condition.

NCT07130864 — Early vs Late Laparoscopic Cholecystectomy After Common Bile Duct Stones Clearance Through Ercp. · NA · recruiting
NCT05169073 — Virtual Reality Training for Laparoscopic Cholecystectomy · NA · recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03386201 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 29 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03386201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing